Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03674424
Title Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jules Bordet Institute

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

transitional cell carcinoma


Avelumab + Gemcitabine + Paclitaxel

Avelumab + Cisplatin + Doxorubicin + Methotrexate + Vinblastine


Avelumab + Cisplatin + Gemcitabine

Age Groups: adult | senior
Covered Countries

No variant requirements are available.